
FDA Approves Johnson & Johnson Nasal Spray for Depression
As a follow up to his ADHD 201 at the APSARD Annual Conference on comorbidities, APSARD President interviewed on CNBC for a breakthrough depression indication.
Read article: https://www.cnbc.com/2025/01/21/fda-approves-johnson-johnson-nasal-spray-spravato-for-depression.html